Innovent to present multiple r&d results of general biomedicine pipeline at the ada's 85th scientific sessions

San francisco and suzhou, china , june 12, 2025 /prnewswire/ -- innovent biologics, inc. ("innovent") (hkex: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the american diabetes association's® (ada) 85th scientific sessions in chicago, u.s. from june 20 -23. innovent will orally present the first phase 3 study of mazdutide in chinese adults with t2d (dreams-1).
GM Ratings Summary
GM Quant Ranking